Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free QNCX Stock Alerts

Quince Therapeutics (QNCX) Financials

Quince Therapeutics logo
$18.88 +0.21 (+1.12%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$18.46 -0.42 (-2.22%)
As of 07/17/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Quince Therapeutics

Annual Income Statements for Quince Therapeutics

This table shows Quince Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -12 -37 -77 -90 -52 -29 -57 -84
Consolidated Net Income / (Loss)		 -12 -37 -77 -90 -52 -31 -57 -84
Net Income / (Loss) Continuing Operations		 -12 -37 -77 -90 -52 -31 -57 -84
Total Pre-Tax Income 		-12 -37 -77 0.00 -52 -32 -57 -81
Total Operating Income		 -12 -39 -79 -90 -52 -35 -57 -58
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 12 39 79 90 52 35 57 58
Selling, General & Admin Expense		 2.03 8.95 18 30 26 18 18 15
Research & Development Expense		 10 30 61 61 25 9.45 19 35
Impairment Charge		 - - - 0.00 0.83 5.90 17 0.00
Other Special Charges / (Income)		 - - - - - - 3.99 7.64
Total Other Income / (Expense), net		 -0.36 2.19 2.04 0.37 0.07 3.04 0.54 -23
Interest & Investment Income		 0.81 2.19 2.04 0.62 1.07 3.48 2.93 1.24
Other Income / (Expense), net		 -0.21 0.00 0.00 -0.25 -1.00 -0.10 -2.39 -24
Income Tax Expense		 - - - 0.00 -0.28 -0.20 0.09 3.21
Basic Earnings per Share		 ($3.71) ($1.94) ($2.63) ($3.03) ($1.54) ($0.84) ($1.31) ($1.68)
Weighted Average Basic Shares Outstanding		 3.36M 19.03M 29.18M 29.72M 33.50M 37.24M 43.26M 50.10M
Diluted Earnings per Share		 ($3.71) ($1.94) ($2.63) ($3.03) ($1.54) ($0.84) ($1.31) ($1.68)
Weighted Average Diluted Shares Outstanding		 3.36M 19.03M 29.18M 29.72M 33.50M 37.24M 43.26M 50.10M

Quarterly Income Statements for Quince Therapeutics

This table shows Quince Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.19 -6.41 -11 -28 -5.49 -12 -15 -16 -13 -39 36
Consolidated Net Income / (Loss)		 -5.35 -8.89 -11 -28 -5.49 -12 -15 -16 -13 -39 36
Net Income / (Loss) Continuing Operations		 -5.35 -8.89 -11 -28 -5.49 -12 -15 -16 -13 -39 36
Total Pre-Tax Income 		-5.35 -8.84 -11 -28 -5.48 -12 -15 -16 -13 -36 31
Total Operating Income		 -6.09 -9.99 -11 -28 -5.86 -12 -15 -10 -13 -19 -15
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 6.09 9.99 11 28 5.86 12 15 10 13 19 15
Selling, General & Admin Expense		 4.66 4.98 4.97 4.70 3.63 4.28 4.79 3.34 3.28 3.64 4.27
Research & Development Expense		 1.43 3.43 3.70 4.15 4.92 5.83 8.15 6.55 8.08 13 6.85
Impairment Charge		 0.00 - - 17 0.00 - 0.00 0.00 0.00 - 68
Other Special Charges / (Income)		 - - 2.55 2.22 -2.68 1.90 1.92 0.53 2.07 3.12 -64
Total Other Income / (Expense), net		 0.74 1.14 0.10 0.50 0.38 -0.44 -0.13 -5.56 -0.06 -17 45
Interest & Investment Income		 0.96 1.01 0.89 0.82 0.68 0.54 0.41 0.31 0.30 0.23 0.16
Other Income / (Expense), net		 -0.22 0.47 -0.40 0.09 -0.30 -1.78 -0.53 -5.37 -0.36 -18 45
Income Tax Expense		 0.00 0.05 0.03 0.04 0.01 0.01 0.05 0.07 -0.05 3.15 -5.34
Basic Earnings per Share		 ($0.15) ($0.21) ($0.26) ($0.64) ($0.13) ($0.28) ($3.42) ($0.34) ($0.25) ($0.75) $3.60
Weighted Average Basic Shares Outstanding		 36.07M 37.24M 43.01M 43.10M 43.16M 43.26M 4.39M 46.69M 53.95M 50.10M 9.12M
Diluted Earnings per Share		 ($0.15) ($0.21) ($0.26) ($0.64) ($0.13) ($0.28) ($3.42) ($0.34) ($0.25) ($0.75) $2.88
Weighted Average Diluted Shares Outstanding		 36.07M 37.24M 43.01M 43.10M 43.16M 43.26M 4.39M 46.69M 53.95M 50.10M 9.19M
Weighted Average Basic & Diluted Shares Outstanding		 42.87M 43.22M 43.22M 43.28M 44.00M 44.00M 45.47M 53.71M 55.68M 0.00 16.30M

Annual Cash Flow Statements for Quince Therapeutics

This table details how cash moves in and out of Quince Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 17 26 16 2.88 -25 -24 -15 -0.40
Net Cash From Operating Activities		 -12 -33 -51 -63 -44 -18 -32 -41
Net Cash From Continuing Operating Activities		 -12 -33 -51 -63 -44 -18 -32 -41
Net Income / (Loss) Continuing Operations		 -12 -37 -77 -90 -52 -31 -57 -84
Consolidated Net Income / (Loss)		 -12 -37 -77 -90 -52 -31 -57 -84
Depreciation Expense		 0.05 0.19 0.33 0.34 0.20 0.32 0.19 0.14
Amortization Expense		 -0.35 -0.81 0.64 0.88 -0.11 -2.02 -2.35 -1.01
Non-Cash Adjustments To Reconcile Net Income		 1.47 2.42 15 30 18 11 23 28
Changes in Operating Assets and Liabilities, net		 -0.39 1.90 10 -4.26 -10 3.31 3.64 15
Net Cash From Investing Activities		 -47 -18 -52 59 18 -5.76 22 23
Net Cash From Continuing Investing Activities		 -47 -18 -52 59 18 -5.76 22 23
Purchase of Property, Plant & Equipment		 -0.21 -0.06 -0.05 -0.18 -0.13 -0.16 -0.26 -0.35
Purchase of Investments		 -55 -135 -187 -39 -75 -114 -90 -34
Sale and/or Maturity of Investments		 8.70 118 135 98 82 111 112 58
Net Cash From Financing Activities		 76 77 119 6.81 0.71 0.14 -4.78 18
Net Cash From Continuing Financing Activities		 76 77 119 6.81 0.71 0.14 -4.78 18
Issuance of Common Equity		 0.00 78 118 0.00 0.61 - 0.00 11
Other Financing Activities, net		 0.02 -0.46 1.25 6.81 0.10 0.14 -4.78 6.48
Effect of Exchange Rate Changes		 - 0.00 0.00 0.06 - 0.08 0.23 -0.11
Cash Interest Paid		 - - - - - - 0.00 0.23

Quarterly Cash Flow Statements for Quince Therapeutics

This table details how cash moves in and out of Quince Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.02 -0.88 1.06 -14 -5.22 3.54 1.56 9.06 -10 -0.64 12
Net Cash From Operating Activities		 -4.82 -6.08 -8.35 -8.74 -7.26 -7.55 -9.60 -11 -9.93 -10 -7.63
Net Cash From Continuing Operating Activities		 -4.82 -6.08 -8.35 -8.74 -7.26 -7.55 -9.60 -11 -9.93 -10 -7.63
Net Income / (Loss) Continuing Operations		 -5.35 -8.89 -11 -28 -5.49 -12 -15 -16 -13 -39 36
Consolidated Net Income / (Loss)		 -5.35 -8.89 -11 -28 -5.49 -12 -15 -16 -13 -39 36
Depreciation Expense		 - 0.30 0.04 0.04 0.09 0.02 0.03 0.04 0.04 0.04 0.04
Amortization Expense		 -0.71 -0.71 -0.65 -0.62 -0.59 -0.49 -0.36 -0.24 -0.24 -0.19 -0.06
Non-Cash Adjustments To Reconcile Net Income		 1.39 1.20 1.63 19 1.58 1.62 1.80 6.20 1.48 19 23
Changes in Operating Assets and Liabilities, net		 -0.15 2.02 1.78 0.94 -2.85 3.76 3.95 -1.37 2.23 11 -67
Net Cash From Investing Activities		 3.64 5.39 8.91 -4.98 7.11 11 11 6.04 -1.78 8.07 12
Net Cash From Continuing Investing Activities		 3.64 5.39 8.91 -4.98 7.11 11 11 6.04 -1.78 8.07 12
Purchase of Property, Plant & Equipment		 - -0.02 -0.04 -0.04 -0.05 -0.13 -0.15 -0.13 -0.07 -0.00 0.00
Purchase of Investments		 -45 -19 -39 -46 -3.84 - -1.95 -12 -16 -4.92 0.00
Sale and/or Maturity of Investments		 49 27 48 41 11 11 13 18 14 13 12
Net Cash From Financing Activities		 0.01 0.06 0.19 0.04 -5.00 - 0.09 14 1.38 2.03 9.44
Net Cash From Continuing Financing Activities		 0.01 0.06 0.19 0.04 -5.00 - 0.09 14 1.38 2.03 9.44
Repayment of Debt		 - - - - - - 0.00 - - - -5.55
Issuance of Common Equity		 - - - - - - 0.00 - - - 15
Other Financing Activities, net		 0.01 0.06 0.19 0.04 -5.00 - 0.09 2.99 1.38 2.03 0.00
Effect of Exchange Rate Changes		 0.16 -0.25 0.31 -0.24 -0.06 0.22 0.18 0.02 -0.04 -0.27 -1.46
Cash Interest Paid		 - - 0.00 - - - 0.05 0.06 0.06 0.06 0.03

Annual Balance Sheets for Quince Therapeutics

This table presents Quince Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 73 124 189 133 104 168 114 94
Total Current Assets		 73 106 138 112 94 77 44 23
Cash & Equivalents		 25 51 67 70 45 21 6.21 5.81
Short-Term Investments		 47 49 67 37 46 54 35 12
Prepaid Expenses		 0.87 6.19 4.04 4.87 3.57 2.38 3.25 5.14
Plant, Property, & Equipment, net		 0.28 0.71 0.43 0.26 0.39 0.23 0.32 0.60
Total Noncurrent Assets		 0.01 18 51 21 9.77 90 70 70
Intangible Assets		 - - - 0.00 5.90 64 60 68
Other Noncurrent Operating Assets		 0.01 0.84 0.71 1.36 0.29 8.93 10 2.21
Total Liabilities & Shareholders' Equity		 73 124 189 133 104 168 114 94
Total Liabilities		 1.46 8.89 17 15 3.32 83 84 129
Total Current Liabilities		 1.46 8.89 17 14 3.07 9.57 7.28 43
Short-Term Debt		 - - - - 0.00 4.10 0.00 30
Accounts Payable		 0.50 3.08 3.56 4.91 0.57 2.03 2.90 2.22
Accrued Expenses		 0.96 5.82 13 9.31 2.50 3.44 4.38 11
Total Noncurrent Liabilities		 0.00 0.00 0.21 0.42 0.25 73 77 86
Other Noncurrent Operating Liabilities		 - 0.00 0.21 0.42 0.00 55 58 86
Total Equity & Noncontrolling Interests		 -33 115 172 119 101 85 30 -36
Total Preferred & Common Equity		 -33 115 172 119 101 85 30 -36
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -33 115 172 119 101 85 30 -36
Common Stock		 0.25 185 319 355 389 402 407 419
Retained Earnings		 -33 -70 -147 -237 -288 -320 -376 -460
Accumulated Other Comprehensive Income / (Loss)		 -0.05 0.06 0.31 -0.08 -0.29 3.05 -0.04 5.75

Quarterly Balance Sheets for Quince Therapeutics

This table presents Quince Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 85 159 135 127 107 117 110 27
Total Current Assets		 85 70 63 52 34 37 29 26
Cash & Equivalents		 22 22 7.89 2.68 7.77 17 6.45 18
Short-Term Investments		 62 46 52 45 24 18 20 0.00
Prepaid Expenses		 1.45 2.62 3.99 3.87 2.23 2.64 2.91 7.42
Plant, Property, & Equipment, net		 0.01 0.23 0.25 0.21 0.45 0.57 0.62 0.55
Total Noncurrent Assets		 0.21 89 71 75 73 79 80 0.49
Intangible Assets		 0.00 62 62 65 62 68 68 0.00
Other Noncurrent Operating Assets		 0.13 9.04 9.35 10 10 12 12 0.49
Total Liabilities & Shareholders' Equity		 85 159 135 127 107 117 110 27
Total Liabilities		 2.25 85 88 82 89 105 109 11
Total Current Liabilities		 2.25 9.84 10 5.43 8.36 7.47 26 8.77
Short-Term Debt		 - 4.75 5.00 0.00 - - 18 0.00
Accounts Payable		 0.41 2.07 2.41 1.62 3.01 1.76 3.40 5.39
Accrued Expenses		 1.84 3.02 2.92 3.80 5.35 5.71 5.12 3.38
Total Noncurrent Liabilities		 0.00 75 78 76 80 98 83 2.18
Other Noncurrent Operating Liabilities		 - 57 59 56 60 75 77 2.18
Total Equity & Noncontrolling Interests		 83 74 47 45 19 12 1.06 16
Total Preferred & Common Equity		 83 74 47 45 19 12 1.06 16
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 83 74 47 45 19 12 1.06 16
Common Stock		 393 403 404 406 408 413 416 436
Retained Earnings		 -311 -331 -359 -364 -392 -408 -421 -425
Accumulated Other Comprehensive Income / (Loss)		 0.52 1.83 1.09 3.42 1.96 6.16 6.29 4.61

Annual Metrics And Ratios for Quince Therapeutics

This table displays calculated financial ratios and metrics derived from Quince Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 26,852,483.00 29,497,999.00 29,877,608.00 36,130,306.00 42,868,947.00 44,001,643.00 55,681,490.00
DEI Adjusted Shares Outstanding		 0.00 26,852,483.00 29,497,999.00 29,877,608.00 36,130,306.00 42,868,947.00 4,400,164.00 5,568,149.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.37 -2.60 -3.01 -1.43 -0.67 -12.92 -15.08
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -215.18% -95.83% -14.65% 40.77% 31.18% -69.78% -34.04%
EBIT Growth		 0.00% -217.79% -101.42% -14.79% 41.47% 34.50% -71.85% -37.44%
NOPAT Growth		 0.00% -223.20% -101.42% -14.48% 42.41% 33.44% -65.47% -1.37%
Net Income Growth		 0.00% -196.41% -107.81% -17.04% 42.56% 39.25% -81.07% -47.78%
EPS Growth		 0.00% 47.71% -35.57% -15.21% 49.17% 45.45% -55.95% -28.24%
Operating Cash Flow Growth		 0.00% -184.54% -52.71% -23.84% 30.02% 58.46% -74.42% -29.84%
Free Cash Flow Firm Growth		 0.00% 0.00% -66.96% -51.28% 23.40% 12.52% 63.91% 14.37%
Invested Capital Growth		 0.00% -288.18% -946.30% 32.22% 183.86% 303.23% -86.64% -726.42%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -28.85% -10.81% -3.41% 24.31% -11.30% -7.55% -43.39%
EBIT Q/Q Growth		 0.00% -30.30% -11.13% -3.36% 24.75% -11.03% -7.71% -44.88%
NOPAT Q/Q Growth		 0.00% -30.30% -11.13% -3.07% 47.45% -12.01% -3.67% -14.47%
Net Income Q/Q Growth		 0.00% -31.74% -11.91% -3.27% 25.70% -11.99% -6.69% -47.39%
EPS Q/Q Growth		 0.00% 45.66% -97.74% -3.06% 30.94% -16.67% -5.65% -38.84%
Operating Cash Flow Q/Q Growth		 0.00% -26.53% -4.80% -1.85% 16.31% -1.35% -4.84% -7.61%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -9.37% -5.91% 37.62% -176.50% 68.08% 12.15%
Invested Capital Q/Q Growth		 0.00% -48.45% -21.24% -3.14% 31.27% 16,310.00% -69.27% -199.27%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 0.00% 99.45% 99.38% 100.15% 103.98%
Interest Burden Percent		 101.23% 94.41% 97.41% 0.00% 97.99% 90.96% 95.09% 98.48%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -17.47% -39.57% -53.42% -61.85% -47.14% -33.81% -98.63% 3,016.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -752.03% -261.45% -103.88% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 7.98% -17.54% -53.42% -61.85% -47.14% -33.81% -98.63% 3,016.49%
Return on Equity Simple (ROE_SIMPLE)		 38.24% -32.02% -44.61% -75.85% -51.36% -36.89% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.48 -27 -55 -63 -36 -24 -40 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.57% -10.15% -14.37% -17.18% -13.83% -9.45% -39.83% -627.08%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -23.62% -90.18% 764.20%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -12 -39 -79 -91 -53 -35 -60 -82
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -40 -78 -89 -53 -36 -62 -83
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 13.05 4.76 3.18 0.23 0.53 2.73 0.00
Price to Tangible Book Value (P/TBV)		 0.00 13.05 4.76 3.18 0.24 11.89 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 15.16 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.21 0.48 -0.85
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.16 0.48 0.00
Financial Leverage		 -1.00 -1.01 -1.05 -1.07 -1.01 -0.81 -0.73 2.48
Leverage Ratio		 1.02 1.06 1.09 1.11 1.08 1.46 2.45 -37.36
Compound Leverage Factor		 1.03 1.00 1.06 0.00 1.06 1.33 2.33 -36.79
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 17.09% 32.21% -571.44%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 4.00% 0.00% -571.44%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 13.09% 32.21% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 145.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -45.68% 100.00% 100.00% 100.00% 100.00% 82.91% 67.79% 671.44%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.48 -0.23 -0.37
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 1.58 0.43 -0.15
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.37 -0.23 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.72 -0.36 -0.75
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 2.37 0.66 -0.31
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.55 -0.36 0.00
Altman Z-Score		 30.87 100.83 26.89 11.60 -0.35 -2.54 -5.35 -9.18
Noncontrolling Interest Sharing Ratio		 145.68% 55.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 49.82 11.93 8.11 7.85 30.55 8.09 6.05 0.53
Quick Ratio		 49.22 11.23 7.87 7.51 29.38 7.84 5.60 0.41
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -27 -44 -67 -51 -45 -16 -14
Operating Cash Flow to CapEx		 -5,516.51% -60,503.64% -97,726.92% -34,962.22% -69,901.59% -26,131.43% -12,414.01% -11,768.47%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -133.01 0.00 0.00
Operating Cash Flow to Interest Expense		 -12.22 0.00 0.00 0.00 0.00 -54.12 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -12.44 0.00 0.00 0.00 0.00 -54.33 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -0.30 -1.15 -12 -8.15 6.83 28 3.68 -23
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.85 -11 3.87 15 21 -24 -27
Enterprise Value (EV)		 107 1,391 635 250 -71 -13 56 199
Market Capitalization		 75 1,507 819 377 23 45 82 187
Book Value per Share		 ($9.70) $4.30 $5.84 $3.97 $2.78 $1.98 $0.69 ($0.64)
Tangible Book Value per Share		 ($9.70) $4.30 $5.84 $3.97 $2.62 $0.09 ($0.68) ($1.86)
Total Capital		 71 115 172 119 101 103 44 -5.32
Total Debt		 0.00 0.00 0.00 0.00 0.00 18 14 30
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 13 14 0.00
Net Debt		 -72 -117 -184 -127 -94 -58 -26 13
Capital Expenditures (CapEx)		 0.21 0.06 0.05 0.18 0.06 0.07 0.26 0.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.59 -2.70 -13 -9.35 0.50 -3.09 -4.03 -7.69
Debt-free Net Working Capital (DFNWC)		 71 97 121 97 91 72 37 10
Net Working Capital (NWC)		 71 97 121 97 91 68 37 -20
Net Nonoperating Expense (NNE)		 3.99 9.56 22 27 15 7.15 17 43
Net Nonoperating Obligations (NNO)		 -72 -117 -184 -127 -94 -58 -26 13
Total Depreciation and Amortization (D&A)		 -0.30 -0.62 0.97 1.22 0.09 -1.70 -2.16 -0.87
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.94) ($2.63) ($3.03) ($1.54) ($0.84) ($13.10) ($16.80)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 29.40M 29.55M 30.15M 33.50M 37.24M 4.33M 5.01M
Adjusted Diluted Earnings per Share		 $0.00 ($1.94) ($2.63) ($3.03) ($1.54) ($0.84) ($13.10) ($16.80)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 29.40M 29.55M 30.15M 33.50M 37.24M 4.33M 5.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.94) ($2.63) ($3.03) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 19.03M 29.18M 29.72M 36.28M 43.22M 4.40M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -8.48 -27 -55 -63 -36 -20 -25 -35
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 -12.88 0.00 0.00 0.00 0.00 -102.73 0.00 0.00
NOPAT to Interest Expense		 -8.86 0.00 0.00 0.00 0.00 -71.70 0.00 0.00
EBIT Less CapEx to Interest Expense		 -13.10 0.00 0.00 0.00 0.00 -102.93 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -9.09 0.00 0.00 0.00 0.00 -71.91 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Quince Therapeutics

This table displays calculated financial ratios and metrics derived from Quince Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 36,382,989.00 42,868,947.00 43,215,233.00 43,215,233.00 43,276,606.00 44,001,643.00 44,001,643.00 45,468,782.00 53,713,798.00 55,681,490.00 55,681,490.00
DEI Adjusted Shares Outstanding		 36,382,989.00 42,868,947.00 43,215,233.00 43,215,233.00 43,276,606.00 4,400,164.00 4,400,164.00 45,468,782.00 53,713,798.00 5,568,149.00 5,568,149.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.14 -0.15 -0.26 -0.64 -0.13 -2.83 -3.42 -0.35 -0.25 -7.09 6.45
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 15.29% -59.40% 8.26% -366.07% 5.03% -43.78% -28.54% 44.23% -109.78% -163.83% 293.40%
EBIT Growth		 23.39% -56.82% 12.01% -393.78% 2.35% -44.87% -32.47% 43.80% -123.76% -171.82% 297.63%
NOPAT Growth		 20.03% -59.16% 13.41% -404.87% 3.79% -20.29% -32.45% 63.01% -129.06% -61.11% -64.78%
Net Income Growth		 32.45% -60.72% 9.02% -467.52% -2.64% -40.07% -34.81% 42.12% -144.76% -216.73% 338.94%
EPS Growth		 31.82% -133.33% 23.53% -357.14% 13.33% -33.33% -34.81% 46.88% -92.31% -167.86% 338.94%
Operating Cash Flow Growth		 28.06% -4.16% -134.04% -128.35% -50.68% -24.25% -14.94% -30.62% -36.75% -38.78% 20.56%
Free Cash Flow Firm Growth		 106.02% -43.04% -154.54% -1,110.58% -1,564.43% 155.81% 136.18% 118.83% 163.30% -14.60% -204.25%
Invested Capital Growth		 -103.27% 303.23% 5,266.74% 1,033.48% 7,149.41% -86.64% -90.84% -194.12% -164.33% -726.42% -210.81%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -14.11% -41.30% -23.20% -134.62% 76.75% -113.92% -10.15% -4.74% 12.53% -169.04% 180.75%
EBIT Q/Q Growth		 -10.88% -50.86% -22.04% -141.90% 78.07% -123.79% -11.60% -5.67% 12.69% -171.86% 181.14%
NOPAT Q/Q Growth		 -9.13% -63.87% -12.34% -151.31% 79.20% -104.88% -23.69% 29.82% -28.80% -44.10% -26.51%
Net Income Q/Q Growth		 -9.52% -66.21% -25.35% -148.71% 80.19% -126.84% -20.65% -6.78% 16.24% -193.54% 191.01%
EPS Q/Q Growth		 -7.14% -40.00% -23.81% -146.15% 79.69% -115.38% -20.65% 0.00% 26.47% -200.00% 191.01%
Operating Cash Flow Q/Q Growth		 -25.90% -26.15% -37.43% -4.62% 16.92% -4.02% -27.13% -18.89% 13.03% -5.57% 27.23%
Free Cash Flow Firm Q/Q Growth		 -58.09% -2,596.23% -18.61% 18.55% 39.27% 195.13% -23.10% -57.61% 104.16% 28.32% -193.88%
Invested Capital Q/Q Growth		 75.04% 16,310.00% -10.94% -74.10% 88.52% -69.27% -38.96% -366.15% -28.85% -199.27% 89.20%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.58% 100.28% 100.13% 100.24% 100.06% 100.31% 100.42% 99.66% 108.66% 117.46%
Interest Burden Percent		 84.80% 92.90% 95.70% 98.55% 88.92% 90.29% 97.36% 101.20% 97.82% 96.87% 100.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.46%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -29.87% -33.81% -36.84% -79.38% -83.18% -98.63% -130.90% -167.04% -247.78% 3,016.49% -192.90%
Cash Return on Invested Capital (CROIC)		 0.00% -261.45% -195.72% -721.74% -424.19% -103.88% -151.95% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -29.87% -33.81% -36.84% -79.38% -83.18% -98.63% -130.90% -167.04% -247.78% 3,016.49% -192.90%
Return on Equity Simple (ROE_SIMPLE)		 -33.71% 0.00% -40.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.27 -6.99 -7.85 -20 -4.10 -8.41 -10 -7.30 -9.40 -14 -17
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.19% -2.52% -4.70% -12.47% -2.39% -9.64% -14.04% -30.00% -19.37% -374.98% 307.57%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.81% -8.49% -29.99% -6.86% -18.91% -30.73% -25.41% -50.60% 254.69% -109.35%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -6.31 -9.52 -12 -28 -6.16 -14 -15 -16 -14 -37 30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.02 -9.92 -12 -29 -6.67 -14 -16 -16 -14 -38 30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.49 0.53 0.61 0.69 0.75 2.73 3.15 6.39 82.68 0.00 0.36
Price to Tangible Book Value (P/TBV)		 0.49 11.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.36
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.05 15.16 18.77 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.21 0.25 0.40 0.33 0.48 0.82 1.45 16.54 -0.85 0.00
Long-Term Debt to Equity		 0.00 0.16 0.18 0.29 0.33 0.48 0.82 1.45 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.81 -0.85 -0.96 -0.91 -0.73 -0.71 -0.99 -0.91 2.48 -1.01
Leverage Ratio		 1.04 1.46 1.54 1.67 1.65 2.45 2.87 4.29 5.14 -37.36 3.90
Compound Leverage Factor		 0.88 1.36 1.47 1.65 1.47 2.21 2.80 4.35 5.03 -36.19 3.92
Debt to Total Capital		 0.00% 17.09% 19.76% 28.62% 24.90% 32.21% 45.10% 59.14% 94.30% -571.44% 0.00%
Short-Term Debt to Total Capital		 0.00% 4.00% 5.14% 7.60% 0.00% 0.00% 0.00% 0.00% 94.30% -571.44% 0.00%
Long-Term Debt to Total Capital		 0.00% 13.09% 14.62% 21.02% 24.90% 32.21% 45.10% 59.14% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 82.91% 80.24% 71.38% 75.10% 67.79% 54.90% 40.86% 5.70% 671.44% 100.00%
Debt to EBITDA		 0.00 -0.48 -0.52 -0.33 -0.26 -0.23 -0.23 -0.34 -0.30 -0.37 0.00
Net Debt to EBITDA		 0.00 1.58 1.41 0.70 0.57 0.43 0.25 0.35 0.15 -0.15 0.00
Long-Term Debt to EBITDA		 0.00 -0.37 -0.38 -0.24 -0.26 -0.23 -0.23 -0.34 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.72 -0.79 -0.48 -0.39 -0.36 -0.36 -0.56 -0.49 -0.75 0.00
Net Debt to NOPAT		 0.00 2.37 2.16 1.05 0.85 0.66 0.38 0.59 0.25 -0.31 0.00
Long-Term Debt to NOPAT		 0.00 -0.55 -0.59 -0.36 -0.39 -0.36 -0.36 -0.56 0.00 0.00 0.00
Altman Z-Score		 6.68 -2.04 -2.37 -3.72 -3.50 -4.03 -4.91 -4.58 -5.26 -7.61 -17.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 37.80 8.09 7.16 6.15 9.53 6.05 4.05 5.00 1.12 0.53 2.92
Quick Ratio		 37.16 7.84 6.89 5.76 8.82 5.60 3.78 4.65 1.01 0.41 2.07
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1.11 -28 -33 -27 -16 15 12 5.04 10 13 -12
Operating Cash Flow to CapEx		 0.00% -25,325.00% -21,417.95% -22,407.69% -15,782.61% -5,678.20% -6,487.16% -9,059.52% -13,416.22% -262,025.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -81.99 -84.72 -64.51 0.00 0.00 0.00 10.06 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -17.98 -21.53 -21.06 0.00 0.00 0.00 -22.78 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -18.05 -21.63 -21.15 0.00 0.00 0.00 -23.04 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.17 28 25 6.36 12 3.68 2.25 -5.98 -7.71 -23 -2.49
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -5.38 21 25 7.04 12 -24 -22 -12 -20 -27 -4.74
Enterprise Value (EV)		 -43 -13 -4.19 -8.20 0.64 56 42 57 79 199 -13
Market Capitalization		 41 45 45 32 34 82 59 75 88 187 5.65
Book Value per Share		 $2.28 $1.98 $1.73 $1.09 $1.04 $0.69 $0.42 $0.26 $0.02 ($0.64) $0.28
Tangible Book Value per Share		 $2.28 $0.09 ($0.12) ($0.34) ($0.45) ($0.68) ($1.00) ($1.23) ($1.24) ($1.86) $0.28
Total Capital		 83 103 92 66 60 44 34 29 19 -5.32 16
Total Debt		 0.00 18 18 19 15 14 15 17 18 30 0.00
Total Long-Term Debt		 0.00 13 14 14 15 14 15 17 0.00 0.00 0.00
Net Debt		 -83 -58 -50 -41 -33 -26 -16 -18 -8.77 13 -18
Capital Expenditures (CapEx)		 0.00 0.02 0.04 0.04 0.05 0.13 0.15 0.13 0.07 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.31 -3.09 -2.47 -1.33 -1.55 -4.03 -6.13 -4.83 -5.61 -7.69 -1.35
Debt-free Net Working Capital (DFNWC)		 83 72 65 58 46 37 25 30 21 10 17
Net Working Capital (NWC)		 83 68 61 53 46 37 25 30 3.16 -20 17
Net Nonoperating Expense (NNE)		 1.09 1.90 3.30 7.99 1.39 4.05 4.63 8.75 4.04 26 -53
Net Nonoperating Obligations (NNO)		 -83 -58 -50 -41 -33 -26 -16 -18 -8.77 13 -18
Total Depreciation and Amortization (D&A)		 -0.71 -0.40 -0.61 -0.58 -0.51 -0.47 -0.32 -0.20 -0.20 -0.15 -0.03
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.15) ($0.21) ($0.26) ($0.64) ($0.13) ($2.80) ($3.40) ($0.34) ($0.25) ($7.50) $3.60
Adjusted Weighted Average Basic Shares Outstanding		 36.07M 37.24M 43.01M 43.10M 43.16M 4.33M 4.39M 46.69M 53.95M 5.01M 9.12M
Adjusted Diluted Earnings per Share		 ($0.15) ($0.21) ($0.26) ($0.64) ($0.13) ($2.80) ($3.40) ($0.34) ($0.25) ($7.50) $2.88
Adjusted Weighted Average Diluted Shares Outstanding		 36.07M 37.24M 43.01M 43.10M 43.16M 4.33M 4.39M 46.69M 53.95M 5.01M 9.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.87M 43.22M 43.22M 43.28M 44.00M 4.40M 4.55M 53.71M 55.68M 0.00 16.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.27 -6.99 -6.07 -6.19 -5.98 -7.08 -9.05 -6.93 -7.95 -11 -7.78
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -28.16 -29.94 -67.71 0.00 0.00 0.00 -31.52 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -20.68 -20.24 -47.55 0.00 0.00 0.00 -14.57 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -28.23 -30.04 -67.81 0.00 0.00 0.00 -31.77 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -20.75 -20.34 -47.65 0.00 0.00 0.00 -14.82 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Quince Therapeutics’ latest quarter shows a mixed but improving liquidity picture, while the core business remains unprofitable and still does not generate revenue. The most notable development in Q1 2026 was a large net income gain of $35.9 million, but that result was heavily influenced by $45.0 million of other income, likely tied to a non-operating item, rather than operating performance. Excluding that, the company still posted a negative operating result and burned cash from operations.

Over the last four years, Quince has consistently reported zero revenue, so the investment story continues to center on expense control, balance-sheet strength, and financing activity rather than sales growth. On that front, the company has relied on a mix of cash, investments, and share issuance to fund operations.

  • Q1 2026 net income was positive at $35.9 million, a sharp improvement from prior quarters, although it was driven mainly by non-operating income.
  • Cash and equivalents increased to $18.2 million at the end of Q1 2026 from $16.8 million in Q2 2025 and $7.8 million in Q1 2025, helped by financing and asset sales.
  • Total current assets were $25.6 million in Q1 2026, and the company remained in a net cash position on a current-asset basis.
  • Net cash from investing activities was positive $12.0 million in Q1 2026, reflecting sale/maturity of investments.
  • Q1 2026 included $14.9 million of common equity issuance, which provided needed funding and supported the cash balance.
  • Research and development spending fell to $6.8 million in Q1 2026 from $12.6 million in Q4 2025 and $8.1 million in Q3 2025, suggesting a lower burn rate in the latest quarter.
  • SG&A also declined to $4.3 million in Q1 2026 from $3.6 million in Q4 2025 and $4.8 million in Q1 2025, though expenses remain meaningful for a company with no revenue.
  • Shares outstanding have been highly dilutive over time, with weighted average basic shares rising from 4.4 million in Q1 2025 to 9.1 million in Q1 2026.
  • The company generated negative operating cash flow of $7.6 million in Q1 2026, showing that the business still consumes cash in day-to-day operations.
  • Quince reported no revenue in every quarter provided, so profitability remains dependent on financing and one-time items rather than sales.
  • Balance-sheet equity has eroded materially over time, with total common equity falling from $74.2 million in Q1 2024 to $15.7 million in Q1 2026.
  • Total liabilities rose to $10.9 million in Q1 2026 from $8.5 million in Q1 2025, while retained earnings remained deeply negative at $424.5 million.

Looking at the trend across the last several quarters, Quince Therapeutics has shown improved cash preservation at times, but the underlying business is still characterized by persistent losses, no revenue, and dependence on external financing. The big Q1 2026 profit figure is encouraging on the surface, but investors should note that it does not yet reflect a sustainable operating turnaround.

07/19/26 12:44 AM ETAI Generated. May Contain Errors.

Quince Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Quince Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Quince Therapeutics' net income appears to be on an upward trend, with a most recent value of -$83.98 million in 2025, rising from -$12.48 million in 2018. The previous period was -$56.83 million in 2024. Find out what analysts predict for Quince Therapeutics in the coming months.

Quince Therapeutics' total operating income in 2025 was -$58.07 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $58.07 million

Over the last 7 years, Quince Therapeutics' total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

Quince Therapeutics' total liabilities were at $129.24 million at the end of 2025, a 53.2% increase from 2024, and a 8,770.1% increase since 2018.

In the past 7 years, Quince Therapeutics' cash and equivalents has ranged from $5.81 million in 2025 to $69.72 million in 2021, and is currently $5.81 million as of their latest financial filing in 2025.

Over the last 7 years, Quince Therapeutics' book value per share changed from -9.70 in 2018 to -0.64 in 2025, a change of -93.4%.


Related Companies

Financial statements for NASDAQ:QNCX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel